Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

SPI Pharmaceuticals

Executive Summary

ICN subsidiary establishes a 75/25 joint venture with Galenika Pharmaceuticals, the largest drug company in Yugoslavia. SPI, which will have the controlling interest, says the new company will have consolidated sales of $370 mil., with 7,400 employees and 18 manufacturing and distribution facilities in six countries. Subject to final approval by the Yugoslavian government, the deal calls for SPI to invest $50 mil. in cash plus properties, equipment and other technological and intellectual properties, bringing the total to $360 mil. ICN Chairman Milan Panic was born in Yugoslavia and later emigrated to the U.S.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS018427

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel